[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Contact us::
Site Facilities::
Impact Factor 2022: 1.4
Cite Score 2023: 1.9
SJR 2023: 0.289
SNIP 2023: 0.327
Publication Charge
►Publication Fee
In Press
 In Press Articles
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
:: Volume 14, Issue 3 (Summer 2023) ::
Caspian J Intern Med 2023, 14(3): 553-559 Back to browse issues page
Chromium and lead levels and alteration in DDPH inhibition in patients with breast cancer undergoing chemotherapy
Fatemeh Pakmanesh , Soleiman Mahjoub , Nahid Neamati , Daryush Moslemi
Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. , moslemi_d@yahoo.com
Abstract:   (1207 Views)

Background: Recently the carcinogenic and toxic effects of some heavy metals such as chromium (Cr), and lead (Pb) through the mechanism of oxidative stress have been reported. Due to the various consequences of chemotherapeutic treatments on body hemostasis, the present study aimed to evaluate the effect of Adriamycin 60 mg/m2 and Cytoxan 600 mg/m2 (AC) chemotherapy on the serum levels of Cr, Pb, and the percent α-diphenyl-β-picrylhydrazyl (DPPH) inhibition.
Methods: This study was performed on 50 patients with breast cancer at two separate sampling times, the first at the initiation of chemotherapy and the last at the end of three courses of the AC chemotherapy treatment. Serum levels of Cr and Pb were measured using atomic absorption spectrophotometry. The percent DPPH inhibition (% I) and also the effect of age and stage of the disease on the mentioned variables were evaluated. Statistical comparison of the obtained results before and after chemotherapy was performed using paired sample t-test. Intra-group evaluation of age and disease stages was done using an independent sample t-test.
Results: A significant decrease was observed in the percent DPPH inhibition after 3 courses of chemotherapy (p<0.001). Cr and also Pb were significantly higher in patients with breast cancer after AC chemotherapy (p<0.001).
Conclusion: According to the results, AC chemotherapy in patients with breast cancer is associated with higher levels of Cr and Pb, which can eventually lead to worsened oxidative stress status in affected patients. However, it seems that these changes do not necessarily depend on age and the stage of the disease.


Keywords: Breast cancer, Chemotherapy, Adriamycin, Cytoxan, the percent DPPH inhibition, Chromium, Lead.
Full-Text [PDF 253 kb]   (518 Downloads)    
Type of Study: Original Article | Subject: Biochimestry
Received: 2022/11/27 | Accepted: 2023/03/7 | Published: 2023/05/9
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Pakmanesh F, Mahjoub S, Neamati N, Moslemi D. Chromium and lead levels and alteration in DDPH inhibition in patients with breast cancer undergoing chemotherapy. Caspian J Intern Med 2023; 14 (3) :553-559
URL: http://caspjim.com/article-1-3766-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 14, Issue 3 (Summer 2023) Back to browse issues page
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.06 seconds with 40 queries by YEKTAWEB 4657